Squarepoint’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Squarepoint’s Portfolio TBIO Stock Details TBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,644	Closed	-$293K	–	3738
2021 Q2	$293K	Sell	10,644 -20,828	-66%	-$409K	﹤0.01%	2549
2021 Q1	$519K	Buy	31,472 +19,728	+168%	+$449K	﹤0.01%	1983
2020 Q4	$216K	Sell	11,744 -78,809	-87%	-$1.41M	﹤0.01%	2453
2020 Q3	$1.23M	Buy	90,553 +68,806	+316%	+$1.06M	0.02%	882
2020 Q2	$390K	Buy	+21,747	New	+$328K	0.01%	1438
2020 Q1	–	Sell	-23,711	Closed	-$193K	–	2778
2019 Q4	$193K	Buy	23,711 +10,797	+84%	+$99.6K	﹤0.01%	2236
2019 Q3	$128K	Buy	+12,914	New	+$122K	﹤0.01%	2157

Squarepoint's TBIO Position: Q3 2021 in Review

Squarepoint sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 10,644 shares — an estimated $293K sold.

Squarepoint first reported a position in TBIO in Q3 2019 and held it in 7 quarters. The position peaked at $1.23M in Q3 2020. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.

Squarepoint reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Squarepoint sold 10,644 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $293K.
Squarepoint first reported a position in Translate Bio, Inc. Common Stock in Q3 2019 and held it in 7 quarters.
Squarepoint's Translate Bio, Inc. Common Stock position peaked at $1.23M in Q3 2020.
0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.

Based on Squarepoint's 13F filing for Q3 2021, filed 15 Nov 2021.